This study showed that PPC treatment ameliorated severe ALD in Ppara−/− mice, including reduced markers of hepatocyte damage and death, inflammation, and fibrosis; however, PPC treatment did not improve markers of hepatic steatosis. The gene discussed is PPARA; the disease is fatty liver disease.